Back

CN41144 OCARINA

Official Title

A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis

Study Details

This research study will evaluate the pharmacokinetics (what the body does to the drug), safety and tolerability, of a drug (ocrelizumab) administered subcutaneously (under the skin) to patients with Multiple sclerosis (MS).

Principal Investigator

Dr. Robert Naismith

IRB Number

201912098

Eligibility

1. Participants must be 18 to 65 years of age
2. Participants must have diagnosed MS (RMS or PPMS)

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back